slides · global inventory
Table Data
Tool collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 16,285
Current window 10,531-10,560
Pages 543
Rows per page 30
Tool
10,531-10,560 of 16,285
06
Includes footnotes detailing pricing assumptions, share counts, and leverage calculations.LionTree | Investment Banking Pitch Book | 25 slides · LionTree
Consulting deck Investment bank Beat · Problem & ComplicationLoop · Golden Circle1 hit
07
Includes a footnote regarding production loans.LionTree | Investment Banking Pitch Book | 25 slides · LionTree
Consulting deck Investment bank Beat · Problem & ComplicationLoop · Golden Circle1 hit
39
The chart includes directional arrows indicating which company is favored by the ratio.LionTree | Investment Banking Pitch Book | 41 slides · LionTree
Consulting deck Investment bank 1 hit
11
Micro Focus | Fixed Income Presentation Deck | 52 slidesMicro Focus | Fixed Income Presentation Deck | 52 slides · Micro Focus
Conference presentation Investor relations Beat · Solution & ApproachLoop · Logic Chain1 hit
25
Includes detailed footnotes explaining adjustments for divestitures and specific cost add-backs.Micro Focus | Mergers and Acquisitions Presentation Deck | 29 slides · Micro Focus
Conference presentation Investment bank 1 hit
29
The table shows adjustments for Stock-Based Compensation (SBC) and non-recurring tax expenses.Shopify | Start Up Pitch Deck | 29 slides · Shopify
Pitch deck Investor relations 1 hit
40
The slide includes a disclaimer at the bottom regarding FDA clearance.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
45
The slide includes a disclaimer about FDA clearance status and definitions for (L) and (H) samples.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Complication1 hit
57
Includes technical definitions of error metrics and regulatory disclaimers.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
61
The slide compares the assay's LoD (480 copies/mL) against the CDC Zika test LoD (930 copies/mL).Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
62
n = 3 replicates per test; FDA disclaimer present.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
63
The slide includes a disclaimer that the technology is not FDA cleared.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
64
n = 3 replicates per test; FDA disclaimer present.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
65
The slide includes a disclaimer at the bottom regarding FDA clearance status.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
66
The slide presents experimental validation data for a diagnostic assay.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
67
Includes a standard Theranos FDA disclaimer at the bottom.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
68
Includes FDA disclaimer at the bottom.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Results1 hit
73
This slide outlines technical mitigation strategies for blood sample collection issues.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Results1 hit
79
The slide uses a standard table format to define the parameters of a clinical validation study.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Conclusion1 hit
81
Passing-Bablok regression used for analysis.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Conclusion1 hit
82
This slide is from a Theranos presentation, likely used to establish the scientific rigor of their testing methodology.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Conclusion1 hit
84
Passing-Bablok regression used for analysis.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Conclusion1 hit
85
Theranos | Investor Conference Presentation Deck | 88 slidesTheranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Conclusion1 hit
86
The slide presents clinical validation data for a diagnostic assay.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Conclusion1 hit
24
Includes specific adjustments for debt covenants and reconciliation to Adjusted EBITDA Margin.Yellow Corporation | Investor Presentation Deck | 25 slides · YRC Worldwide
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
25
Includes a footnote regarding non-cash foreign currency gains or losses.Yellow Corporation | Investor Presentation Deck | 25 slides · YRC Worldwide
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
29
Includes specific adjustments for debt covenants and margin calculation.Yellow Corporation | Investor Presentation Deck | 30 slides · Yellow Corporation
Pitch deck Investor relations Beat · Ultimate Achievement1 hit
30
Includes footnote (a) regarding non-cash foreign currency gains or losses.Yellow Corporation | Investor Presentation Deck | 30 slides · Yellow Corporation
Pitch deck Investor relations Beat · Ultimate Achievement1 hit
06
Slide compares national long-haul vs regional short-haul operations with key performance metrics.Yellow Corporation | Investor Presentation Deck | 39 slides · YRC Worldwide
Pitch deck Investor relations Beat · Solution1 hit
23
Focuses on human capital as a competitive moat.Yellow Corporation | Investor Presentation Deck | 39 slides · YRC Worldwide
Pitch deck Investor relations Beat · Traction1 hit